Hikal shows 17% degrowth in Q1 FY23
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.
Sridhar will continue to serve in his current position of Managing Director for as long a period as required until the identification, selection and transition to the new leadership takes place in the company.
The vaccine has been developed by the National Equine Research Center, Hisar (Haryana) in collaboration with the Indian Veterinary Research Institute, Izzatnagar (Bareilly)
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country
Subscribe To Our Newsletter & Stay Updated